Katherine M Dell1, Matthew Matheson2, Erum A Hartung3, Bradley A Warady4, Susan L Furth3. 1. Center for Pediatric Nephrology, Cleveland Clinic Children's, Department of Pediatrics, Case Western Reserve University, Cleveland, OH. Electronic address: Katherine.Dell@case.edu. 2. Department of Epidemiology, Johns Hopkins University, Baltimore, MD. 3. Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA. 4. Division of Pediatric Nephrology, Children's Mercy Hospital, Kansas City, MO.
Abstract
OBJECTIVE: To define glomerular filtration rate (GFR) decline, hypertension (HTN), and proteinuria in subjects with autosomal recessive polycystic kidney disease (ARPKD) and compare with 2 congenital kidney disease control groups in the Chronic Kidney Disease in Children cohort. STUDY DESIGN: GFR decline (iohexol clearance), rates of HTN (ambulatory/casual blood pressures), antihypertensive medication usage, left ventricular hypertrophy, and proteinuria were analyzed in subjects with ARPKD (n = 22) and 2 control groups: aplastic/hypoplastic/dysplastic disorders (n = 44) and obstructive uropathies (n = 44). Differences between study groups were examined with the Wilcoxon rank sum test. RESULTS: Annualized GFR change in subjects with ARPKD was -1.4 mL/min/1.73 m(2) (-6%), with greater decline in subjects age ≥ 10 years (-11.5%). However, overall rates of GFR decline did not differ significantly in subjects with ARPKD vs controls. There were no significant differences in rates of HTN or left ventricular hypertrophy, but subjects with ARPKD had a greater percent on ≥ 3 blood pressure medications (32% vs 0%, P < .0001), more angiotensin-converting enzyme inhibitor use (82% vs 27% vs 36%, P < .0005), and less proteinuria (urine protein: creatinine = 0.1 vs 0.6, P < .005). CONCLUSIONS: This study reports rates of GFR decline, HTN, and proteinuria in a small but well-phenotyped ARPKD cohort. The relatively slow rate of GFR decline in subjects with ARPKD and absence of significant proteinuria suggest that these standard clinical measures may have limited utility in assessing therapeutic interventions and highlight the need for other ARPKD kidney disease progression biomarkers.
OBJECTIVE: To define glomerular filtration rate (GFR) decline, hypertension (HTN), and proteinuria in subjects with autosomal recessive polycystic kidney disease (ARPKD) and compare with 2 congenital kidney disease control groups in the Chronic Kidney Disease in Children cohort. STUDY DESIGN: GFR decline (iohexol clearance), rates of HTN (ambulatory/casual blood pressures), antihypertensive medication usage, left ventricular hypertrophy, and proteinuria were analyzed in subjects with ARPKD (n = 22) and 2 control groups: aplastic/hypoplastic/dysplastic disorders (n = 44) and obstructive uropathies (n = 44). Differences between study groups were examined with the Wilcoxon rank sum test. RESULTS: Annualized GFR change in subjects with ARPKD was -1.4 mL/min/1.73 m(2) (-6%), with greater decline in subjects age ≥ 10 years (-11.5%). However, overall rates of GFR decline did not differ significantly in subjects with ARPKD vs controls. There were no significant differences in rates of HTN or left ventricular hypertrophy, but subjects with ARPKD had a greater percent on ≥ 3 blood pressure medications (32% vs 0%, P < .0001), more angiotensin-converting enzyme inhibitor use (82% vs 27% vs 36%, P < .0005), and less proteinuria (urine protein: creatinine = 0.1 vs 0.6, P < .005). CONCLUSIONS: This study reports rates of GFR decline, HTN, and proteinuria in a small but well-phenotyped ARPKD cohort. The relatively slow rate of GFR decline in subjects with ARPKD and absence of significant proteinuria suggest that these standard clinical measures may have limited utility in assessing therapeutic interventions and highlight the need for other ARPKD kidney disease progression biomarkers.
Authors: Bradley A Warady; Alison G Abraham; George J Schwartz; Craig S Wong; Alvaro Muñoz; Aisha Betoko; Mark Mitsnefes; Frederick Kaskel; Larry A Greenbaum; Robert H Mak; Joseph Flynn; Marva M Moxey-Mims; Susan Furth Journal: Am J Kidney Dis Date: 2015-03-19 Impact factor: 8.860
Authors: Gianluigi Ardissino; Sara Testa; Valeria Daccò; Fabio Paglialonga; Sara Viganò; Cristina Felice-Civitillo; Francesco Battaglino; Alberto Bettinelli; Andrea Bordugo; Valeria Cecchetti; Salvatore De Pascale; Angela La Manna; Salvatore Li Volti; Silvio Maringhini; Giovanni Montini; Marco Pennesi; Leopoldo Peratoner Journal: Arch Dis Child Date: 2012-07-25 Impact factor: 3.791
Authors: Lisa M Guay-Woodford; John J Bissler; Michael C Braun; Detlef Bockenhauer; Melissa A Cadnapaphornchai; Katherine M Dell; Larissa Kerecuk; Max C Liebau; Maria H Alonso-Peclet; Benjamin Shneider; Sukru Emre; Theo Heller; Binita M Kamath; Karen F Murray; Kenneth Moise; Eric E Eichenwald; Jacquelyn Evans; Roberta L Keller; Louise Wilkins-Haug; Carsten Bergmann; Meral Gunay-Aygun; Stephen R Hooper; Kristina K Hardy; Erum A Hartung; Randi Streisand; Ronald Perrone; Marva Moxey-Mims Journal: J Pediatr Date: 2014-07-09 Impact factor: 4.406
Authors: Susan L Furth; Stephen R Cole; Marva Moxey-Mims; Frederick Kaskel; Robert Mak; George Schwartz; Craig Wong; Alvaro Muñoz; Bradley A Warady Journal: Clin J Am Soc Nephrol Date: 2006-07-19 Impact factor: 8.237
Authors: L M Guay-Woodford; C A Galliani; E Musulman-Mroczek; G S Spear; A P Guillot; J Bernstein Journal: Pediatr Nephrol Date: 1998-04 Impact factor: 3.714
Authors: Joshua Samuels; Derek Ng; Joseph T Flynn; Mark Mitsnefes; Tim Poffenbarger; Bradley A Warady; Susan Furth Journal: Hypertension Date: 2012-05-14 Impact factor: 10.190
Authors: George J Schwartz; Michael F Schneider; Paula S Maier; Marva Moxey-Mims; Vikas R Dharnidharka; Bradley A Warady; Susan L Furth; Alvaro Muñoz Journal: Kidney Int Date: 2012-08 Impact factor: 10.612
Authors: Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres Journal: Nat Rev Dis Primers Date: 2018-12-06 Impact factor: 52.329
Authors: Nehna Abdul Majeed; Esperanza Font-Montgomery; Linda Lukose; Joy Bryant; Peter Veppumthara; Peter L Choyke; Ismail B Turkbey; Theo Heller; William A Gahl; Meral Gunay-Aygun Journal: Mol Genet Metab Date: 2020-09-03 Impact factor: 4.797
Authors: Christina J MacAskill; Michael Markley; Susan Farr; Ashlee Parsons; Jacob R Perino; Kimberly McBennett; Katherine Kutney; Mitchell L Drumm; Nicole Pritts; Mark A Griswold; Dan Ma; Katherine M Dell; Chris A Flask; Yong Chen Journal: Radiology Date: 2021-06-08 Impact factor: 29.146
Authors: Erum A Hartung; Katherine M Dell; Matthew Matheson; Bradley A Warady; Susan L Furth Journal: Front Pediatr Date: 2016-08-10 Impact factor: 3.418
Authors: Meredith A Atkinson; Derek K Ng; Bradley A Warady; Susan L Furth; Joseph T Flynn Journal: Pediatr Nephrol Date: 2020-02-03 Impact factor: 3.714